Green: These inhalers tend to be for long-acting beta-agonist preventer medication, most often used to help reduce symptoms of respiratory conditions like asthma or COPD. These must also be taken ...

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

In patients with chronic obstructive pulmonary disease (COPD), the first year of using single-inhaler triple therapy is associated with slightly more major adverse cardiovascular events (MACE) than ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.